Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Acq. announced
Quarterly results
Director departure
Appointed director
Inv. presentation
Auditor change
CC transcript
|
|
QUESTCOR PHARMACEUTICALS INC (QCOR)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 01/10/2011 |
8-K
| Resignation/termination of a director |
| 02/04/2010 |
8-K
| Form 8-K - Current report |
| 10/23/2009 |
8-K
| Resignation/termination of a director|
Docs:
|
"Offer Letter, by and between Questcor Pharmaceuticals, Inc. and Dr. David Young, Pharm.D., Ph.D.",
"Severance Agreement, by and between Questcor Pharmaceuticals, Inc. and Dr. David Young, Pharm.D., Ph.D.",
"QUESTCOR EXPANDS MANAGEMENT TEAM UNION CITY, CA/OCTOBER 22, 2009— Questcor Pharmaceuticals, Inc. announced today that David Young, Pharm.D., Ph.D., currently a member of Questcor's Board of Directors, has been appointed to the newly created position of Chief Scientific Officer, and Sian E. Bigora, Pharm.D. has been appointed to the newly created position of Vice President Regulatory Affairs. Dr. Young , joins Questcor from AGI Therapeutics plc where he served as Executive Director & President, US Operations for the specialty pharmaceutical company since 2006. Dr. Bigora also joins Questcor from AGI Therapeutics where she served as Vice President, Clinical Research and Regulatory Affairs since 2007. Both executives will be based in Questcor's new East Coast offices in Columbia, Maryland. Dr..." |
|
| 09/06/2007 |
8-K
| Resignation/termination of a director |
| 08/22/2007 |
8-K
| Resignation/termination of a director |
| 06/22/2007 |
8-K
| Resignation/termination of a director |
|
|